pamidronic acid indications/contra

Stem definitionDrug idCAS RN
calcium metabolism regulator, pharmaceutical aid 2048 40391-99-9

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • pamidronic acid
  • pamidronate disodium
  • pamidronate
  • pamidronate disodium hydrate
inhibits osteolytic bone lesions; inhibits the mevalonate pathway, which is required for the prenylation of the small GTPase; RN given refers to parent cpd
  • Molecular weight: 235.07
  • Formula: C3H11NO7P2
  • CLOGP: -6.17
  • LIPINSKI: 1
  • HAC: 8
  • HDO: 6
  • TPSA: 161.31
  • ALOGS: -1.17
  • ROTB: 4

Drug dosage:

DoseUnitRoute
60 mg P

Approvals:

DateAgencyCompanyOrphan
Oct. 31, 1991 FDA

FDA Adverse Event Reporting System

scroll-->
MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Osteonecrosis 2256.74 58.63 403 949 10496 3374011
Osteonecrosis of jaw 1512.17 58.63 288 1064 10208 3374299
Bone disorder 731.58 58.63 137 1215 4152 3380355
Tooth extraction 712.03 58.63 129 1223 3234 3381273
Osteomyelitis 341.55 58.63 75 1277 4965 3379542
Impaired healing 338.72 58.63 79 1273 6869 3377638
Pain in jaw 333.21 58.63 76 1276 5982 3378525
Bone debridement 332.10 58.63 48 1304 251 3384256
Sequestrectomy 328.82 58.63 50 1302 389 3384118
Femur fracture 307.81 58.63 74 1278 7314 3377193
Debridement 276.99 58.63 45 1307 556 3383951
Actinomycosis 250.46 58.63 39 1313 359 3384148
Exposed bone in jaw 236.42 58.63 43 1309 1065 3383442
Primary sequestrum 193.64 58.63 33 1319 552 3383955
Atypical femur fracture 186.86 58.63 34 1318 841 3383666
Pain 167.11 58.63 82 1270 71475 3313032
Malignant neoplasm progression 144.71 58.63 50 1302 17743 3366764
Hypocalcaemia 141.40 58.63 38 1314 5783 3378724
Fistula 138.73 58.63 31 1321 2187 3382320
Jaw disorder 137.35 58.63 29 1323 1566 3382941
Infection 134.46 58.63 52 1300 25350 3359157
Jaw operation 133.98 58.63 22 1330 289 3384218
Bone lesion 127.51 58.63 25 1327 928 3383579
Hypercalcaemia 122.64 58.63 31 1321 3706 3380801
Nephrocalcinosis 121.69 58.63 20 1332 264 3384243
Purulent discharge 120.87 58.63 25 1327 1219 3383288
Metastases to bone 113.46 58.63 28 1324 3033 3381474
Tibia fracture 91.53 58.63 19 1333 941 3383566
Tooth abscess 89.31 58.63 22 1330 2360 3382147
Osteosclerosis 88.61 58.63 16 1336 376 3384131

Pharmacologic Action:

scroll-->
SourceCodeDescription
ATC M05BA03 MUSCULO-SKELETAL SYSTEM
DRUGS FOR TREATMENT OF BONE DISEASES
DRUGS AFFECTING BONE STRUCTURE AND MINERALIZATION
Bisphosphonates
FDA EPC N0000175579 Bisphosphonate
FDA Chemical/Ingredient N0000007707 Diphosphonates
MeSH PA D050071 Bone Density Conservation Agents

Drug Use (View source of the data)

scroll-->
DiseaseRelationSNOMED_IDDOID
Osteitis deformans indication 2089002 DOID:5408
Humoral hypercalcemia of malignancy indication 47709007
Osteolytic Bone Metastases of Breast Cancer indication
Osteolytic Lesions of Multiple Myeloma indication
Hypophosphatemia contraindication 4996001
Hypocalcemia contraindication 5291005
Hypovolemia contraindication 28560003
Dehydration contraindication 34095006
Periodontitis contraindication 41565005 DOID:824
Hypokalemia contraindication 43339004
Kidney disease contraindication 90708001 DOID:2527
Hypomagnesemia contraindication 190855004
Pregnancy, function contraindication 289908002
Aseptic necrosis of bone of jaw contraindication 441809006
Thyroid Surgery contraindication
Invasive Dental Procedure contraindication
Drug-induced osteoporosis off-label use 14651005
Bone Metastases off-label use
Prevention of Glucocorticoid-Induced Osteoporosis off-label use

Acid dissociation constants calculated using MoKa v3.0.0

scroll-->
Dissociation levelDissociation constantType (acidic/basic)
pKa1 0.71 acidic
pKa2 4.78 acidic
pKa3 5.76 acidic
pKa4 9.83 acidic
pKa5 13.04 acidic
pKa6 11.49 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

scroll-->
TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Farnesyl pyrophosphate synthase Enzyme INHIBITOR Ki 7.25 CHEMBL CHEMBL
Hypoxanthine-guanine phosphoribosyltransferase Unclassified Ki 4.30 CHEMBL
Farnesyl pyrophosphate synthase Enzyme Ki 6.72 CHEMBL

External reference:

scroll-->
IDSource
DB00282 DRUGBANK_ID
C3714572 UMLSCUI
7259 IUPHAR_LIGAND_ID
D00941 KEGG_DRUG
CHEMBL676 ChEMBL_ID
CHEMBL834 ChEMBL_ID
4674 PUBCHEM_CID
420442001 SNOMEDCT_US
N0000171575 NDFRT
1546406 RXNORM
005066 NDDF
8742T8ZQZA UNII
109552-15-0 SECONDARY_CAS_RN
CHEBI:7903 CHEBI
6305 INN_ID
C019248 MESH_SUPPLEMENTAL_RECORD_UI
210 PDB_CHEM_ID

Pharmaceutical products:

scroll-->
ProductCategoryIngredientsNDCFormQuantityRoute MarketingLabel
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 0069-0107 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 13 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 0069-0109 INJECTION, SOLUTION 9 mg INTRAVENOUS ANDA 13 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 0069-0186 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 0517-0745 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 13 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 0517-0746 INJECTION, SOLUTION 9 mg INTRAVENOUS ANDA 13 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 0703-4075 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 16 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 0703-4085 INJECTION, SOLUTION 9 mg INTRAVENOUS ANDA 16 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-601 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 3 mg INTRAVENOUS ANDA 11 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-602 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 6 mg INTRAVENOUS ANDA 11 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 59923-603 INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION 9 mg INTRAVENOUS ANDA 11 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-324 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-325 INJECTION, SOLUTION 6 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 61703-326 INJECTION, SOLUTION 9 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 63323-734 INJECTION, SOLUTION 3 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 63323-735 INJECTION, SOLUTION 9 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-446 INJECTION 9 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-472 INJECTION 3 mg INTRAVENOUS ANDA 12 sections
Pamidronate Disodium HUMAN PRESCRIPTION DRUG LABEL 1 67457-610 INJECTION 9 mg INTRAVENOUS ANDA 12 sections